

Abstract Plain Language Summaries at Scientific Congresses



What are abstract plain language summaries (APLS)?

APLS use simple visuals, plain language and consistent terminology to describe the research presented at scientific congresses, or meetings. Each APLS represents a small piece of the complete body of data available on the drug and disease area today.

APLS reports represent results of only one study. Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe. The results might be different from the outcome of other studies that researchers have presented in the past. It's important to note that these data are investigational, and the treatments may not be approved in these settings by regulatory agencies.

Presentations will go live on the dates marked below.

WHO ARE APLS FOR?

APLS can help research findings be accessible and understandable to anyone seeking this information. Audiences may include but are not limited to patients, caregivers, and healthcare professionals.

HOW ARE APLS USED?

APLS can help people better understand the research data in presentations at scientific congresses.

WHAT INFORMATION DO APLS INCLUDE?

APLS summarize the original content of a scientific abstract. They describe the main aims and findings of a research study in an easy-to-understand format by following health literacy best practices.

WHY DOES PFIZER DEVELOP APLS?

Research findings often use terms that can be too complex for many non-scientists to understand. APLS provide recent research results in a clear way for non-scientists.



ASCO Genitourinary (GU) Cancers Symposium

San Francisco, CA & Online | February 16-18, 2023

PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES AND ACCOMPANYING SCIENTIFIC PRESENTATIONS AT ASCO GU 2023

Prostate Cancer

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPEC)

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Real-world (RW) prevalence of adverse events (AEs) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPEC)

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-sensitive prostate cancer

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Identifying prostate cancer patient subgroups based on their preferences for key attributes of androgen deprivation therapies

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): Analysis from a US EMR database

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US)

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Real world (rw) racial differences in treatment (tx) patterns and clinical outcomes among patients (pts) with mCRPC

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPEC) in the United States (US)

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

A multi-center, prospective, observational study of patients with prostate cancer being treated with relugolix: OPTYX

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US)

Live Friday, February 17

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Urothelial Cancer

Patient (Pt) perspective on fatigue and its management for advanced prostate cancer (PC) treated with androgen receptor inhibitors (ARIs)

Live Friday, February 17

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy

Live Friday, February 17

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II)

Live Friday, February 17

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Urothelial Cancer

Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC)

Live Friday, February 17

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)

Live Friday, February 17

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Time to event following bacillus Calmette-Guerin therapy initiation in Medicare beneficiaries with intermediate- to high-risk non-muscle invasive bladder cancer, 2010-2019

Live Friday, February 17

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Renal Cancer

C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101

Live Saturday, February 18

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results

Live, Saturday, February 18

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Early Oncology Development

A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

Pan-Oncology

Social determinants of health (SDOH) and survival among patients with metastatic prostate cancer (mPC): A systematic literature review (SLR)

Live Thursday, February 16

[VIEW PLAIN LANGUAGE SUMMARY](#) →

[VIEW PRESENTATION](#) →

